Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Epithelial‐mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4‐ALK translocation2013 · 112 citations
2. 2Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations2014 · 594 citations
3. 3The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer2014 · 856 citations
4. 4Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds1987 · 8,053 citations